Citigroup Inc Arcus Biosciences, Inc. Call Options Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 09, 2023	BUY	$19.7 - $35.71 $39,400 - $71,420	2,000 Added 11.11%	20,000 $413,000
Q3 2022 Nov 10, 2022	BUY	$23.23 - $30.07 $283,406 - $366,854	12,200 Added 210.34%	18,000 $471,000
Q2 2022 Aug 10, 2022	SELL	$17.23 - $37.73 $29,291 - $64,140	-1,700 Reduced 22.67%	5,800 $147,000
Q1 2022 May 12, 2022	SELL	$28.92 - $41.83 $1.24 Million - $1.8 Million	-43,000 Reduced 85.15%	7,500 $237,000
Q3 2021 Nov 10, 2021	BUY	$26.93 - $37.68 $1.36 Million - $1.9 Million	50,500 New	50,500 $1.76 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.